Literature DB >> 28287727

Michael Acceptor-Based Peptidomimetic Inhibitor of Main Protease from Porcine Epidemic Diarrhea Virus.

Fenghua Wang1, Cheng Chen1,2, Kailin Yang3, Yang Xu2, Xiaomei Liu2, Fan Gao2, He Liu2, Xia Chen1, Qi Zhao4, Xiang Liu2, Yan Cai2, Haitao Yang1,2.   

Abstract

Porcine epidemic diarrhea virus (PEDV) causes high mortality in pigs. PEDV main protease (Mpro) plays an essential role in viral replication. We solved the structure of PEDV Mpro complexed with peptidomimetic inhibitor N3 carrying a Michael acceptor warhead, revealing atomic level interactions. We further designed a series of 17 inhibitors with altered side groups. Inhibitors M2 and M17 demonstrated enhanced specificity against PEDV Mpro. These compounds have potential as future therapeutics to combat PEDV infection.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28287727     DOI： 10.1021/acs.jmedchem.7b00103

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


  13 in total

Review 1.  Review on development of potential inhibitors of SARS-CoV-2 main protease (MPro).

Authors:  Soumya Gulab Katre; Alpana Jagdish Asnani; Kumar Pratyush; Nilima Gangadhar Sakharkar; Ashwini Gajanan Bhope; Kanchan Tekram Sawarkar; Vaibhav Santosh Nimbekar
Journal:  Futur J Pharm Sci       Date:  2022-06-21

Review 2.  The SARS-CoV-2 main protease (Mpro): Structure, function, and emerging therapies for COVID-19.

Authors:  Qing Hu; Yuan Xiong; Guang-Hao Zhu; Ya-Ni Zhang; Yi-Wen Zhang; Ping Huang; Guang-Bo Ge
Journal:  MedComm (2020)       Date:  2022-07-14

3.  Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors.

Authors:  Zhenming Jin; Xiaoyu Du; Yechun Xu; Yongqiang Deng; Meiqin Liu; Yao Zhao; Bing Zhang; Xiaofeng Li; Leike Zhang; Chao Peng; Yinkai Duan; Jing Yu; Lin Wang; Kailin Yang; Fengjiang Liu; Rendi Jiang; Xinglou Yang; Tian You; Xiaoce Liu; Xiuna Yang; Fang Bai; Hong Liu; Xiang Liu; Luke W Guddat; Wenqing Xu; Gengfu Xiao; Chengfeng Qin; Zhengli Shi; Hualiang Jiang; Zihe Rao; Haitao Yang
Journal:  Nature       Date:  2020-04-09       Impact factor: 49.962

Review 4.  The main protease and RNA-dependent RNA polymerase are two prime targets for SARS-CoV-2.

Authors:  Zhenming Jin; Haofeng Wang; Yinkai Duan; Haitao Yang
Journal:  Biochem Biophys Res Commun       Date:  2020-11-21       Impact factor: 3.575

Review 5.  What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design.

Authors:  Muya Xiong; Haixia Su; Wenfeng Zhao; Hang Xie; Qiang Shao; Yechun Xu
Journal:  Med Res Rev       Date:  2021-01-18       Impact factor: 12.388

Review 6.  Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19.

Authors:  Wen Cui; Kailin Yang; Haitao Yang
Journal:  Front Mol Biosci       Date:  2020-12-04

7.  Xanthohumol Is a Potent Pan-Inhibitor of Coronaviruses Targeting Main Protease.

Authors:  Yuxi Lin; Ruochen Zang; Yanlong Ma; Zhuoya Wang; Li Li; Siyuan Ding; Rong Zhang; Zhiqiang Wei; Jinbo Yang; Xin Wang
Journal:  Int J Mol Sci       Date:  2021-11-09       Impact factor: 5.923

Review 8.  SARS-CoV-2: Origin, Evolution, and Targeting Inhibition.

Authors:  Shuo Ning; Beiming Yu; Yanfeng Wang; Feng Wang
Journal:  Front Cell Infect Microbiol       Date:  2021-06-17       Impact factor: 5.293

9.  Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.

Authors:  Sirin Theerawatanasirikul; Chih Jung Kuo; Nanthawan Phecharat; Jullada Chootip; Chalermpol Lekcharoensuk; Porntippa Lekcharoensuk
Journal:  Antiviral Res       Date:  2020-09-07       Impact factor: 5.970

Review 10.  COVID-19: inflammatory responses, structure-based drug design and potential therapeutics.

Authors:  Neetu Tripathi; Neeraj Tripathi; Manoj Kumar Goshisht
Journal:  Mol Divers       Date:  2021-01-05       Impact factor: 3.364
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.